Discover why the strongest Medical Affairs strategies combine global scientific influence with the local insight needed to make an impact in real world clinical practice.
Rare disease KOL mapping demands more than publication counts and standard databases. This blog explores why local expertise, hidden networks and overlapping clinical, research and patient roles can make the landscape far more complex than it first appears.
There is a familiar moment in clinical trial recruitment when the numbers begin to cause concern. As recruitment progresses, it becomes clear that the study population is not representative and that some communities are underrepresented. The response is often to translate materials, explore new channels, contact more patient organisations and increase outreach. But by then, many of the decisions affecting participation have already been made.
DOL identification is not a commodity service. Done well, it gives your Medical Affairs team a genuine strategic advantage: access to the people who are shaping the conversation in your therapy area, before your competitors have even found them.
Most advisory boards are built to inform, not to discover. Learn how to design boards that surface real insight through better questions, a more diverse room and space for genuine conversation, instead of quiet validation.
At Scout, we know a powerful KOL map begins with asking the right questions—especially the ones that challenge your assumptions. What are your real therapeutic goals, and who do you truly need to connect with to understand the market? Let’s have a conversation.
